All News
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.
Read Article
Health Literacy: the forgotten social determinant of health?
Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/15gvQxZHNN https://t.co/VqCjZY4tYI
Dr. John Cush RheumNow ( View Tweet)
Abstract 2681: #SDOH factors & SLE risk:
- Low income (AOR=2.779).
- By race/ethnicity NHB (AOR=2.429), Hispanic (AOR=1.616).
Behavioral: Psych distress (AOR=2.127), no exercise (AOR=1.677).
Access: Medicaid (AOR=2.540), transport barriers (AOR=20.394).
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
For daily recaps, content and updates from #ACR24 head to https://t.co/eL0bMhnFiu @RheumNow with input from colleagues in the faculty
@synovialjoints
@bella_mehta
@ericdeinmd
@AkhilSoodMD.
@DrMiniDey
@CaoilfhionnMD
@ebrhuem
@rheumarampa
@Dr_Brian_MD
@AdelaCastro222
@JihaRheum… https://t.co/a3FQjGokhn https://t.co/1g3Fi01HWG
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Hypoxia seems to exacerbate neutrophil activation by ANCA
- enhanced F-Actin polymerization
- enhanced NET formation
Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns?
@RheumNow #ACR24 https://t.co/KxaeMvkd2t
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
In Vivo CAR T Cell Therapy.
A single intralymphatic injection of VivoVec™ particles:
- Generates functional CAR T cells in vivo
- Achieves complete B cell depletion in NHPs without lymphodepletion
- Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Wt ⬇️ = Better #PROs in
👇autoimmune #rheumatic #diseases if > 5% wt loss.
#ACR24 @ACRheum @RheumNow
Didn’t work for non overwt
Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
#Artificial #Intelligence can detect #osteoporosis
On #CXR
To detect #thoracic #vertebral #fractures
> 100000 #chest #radiographs - test and validation cohorts found + results on ROC
Helpful -sometimes vertebral changes are
Not read on CXRs
#ACR24 @RheumNow @ACRheum #2116 https://t.co/NxEaH0AKJv
Links:
Janet Pope Janetbirdope ( View Tweet)
RheumNow Day 3 Recap: ACR Convergence 2024 Highlights https://t.co/jFIATPKlp7
Links:
Dr. John Cush RheumNow ( View Tweet)
Pathophysiological pathways in neuropsychiatric SLE. 2 components:
-Ischaemic
-Inflammatory
Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww
Links:
Richard Conway RichardPAConway ( View Tweet)
A New ACR
Dr. Jack Cush highlights a few notable changes to the ACR meeting format this year, and offers pointers on the best way to stay informed and abreast of reporting from the #ACR24 Convergence meeting in Washington, DC.
https://t.co/YmI6s1TanV https://t.co/hsByGEBtnz
Links:
Dr. John Cush RheumNow ( View Tweet)
A#2649
Relapsing Polychondritis
Latent Class Analysis to define clinical phenotypes of heterogeneous dx
Type 1- ear, nose, subglottic stenosis
2- tracheo/bronchomalacia
3- absence tracheomalacia
Decision tree to classify pts in subgroups
#ACR24 @RheumNow https://t.co/xpZedPVl7f
Links:
Eric Dein ericdeinmd ( View Tweet)
Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutaneous vasculitis- he got worse with immunosuppression. Imaging and histology shown #ThievesMarket #ACR24 @RheumNow https://t.co/FjJ0Sk0Kxt
Links:
TheDaoIndex KDAO2011 ( View Tweet)
Neuroimaging is done to support the diagnosis of CNS #lupus but only 75% reveal abnormal brain MRI.
📌 It is more useful in pts with local deficits than diffuse.
📌 poorly correlated with cognitive dysfunction & psych phenotypes.
@Rheumnow #ACR24 @rheumarhyme @theactiverheum https://t.co/HjNbVBaOHv
sheila RHEUMarampa ( View Tweet)
The different NPSLE syndromes 👇
Highlighted in yellow are the most common manifestations. 🧠
- Cognitive dysfunction
- Mood disorder
- Anxiety disorder
@RheumNow #ACR24 https://t.co/1I7OVPT6DK
sheila RHEUMarampa ( View Tweet)
Dr @ZahiTouma discusses the attribution rules for the NPSLE syndromes
Attribute to #SLE if
- onset of NP is near the SLE dx
- absence of concurrent nonSLE factors
- ⬇️ frequency of NP events in the gen pop'n
- diagnostic tools favor NPSLE
@RheumNow #ACR24 https://t.co/e1xBK4Xzsw
sheila RHEUMarampa ( View Tweet)
